Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Hans von Holst,

Hans von Holst,

Karolinska Institutet, Sweden

Title: Cytotoxic brain tissue edema as a complication to stroke and traumatic brain injury – How to deal with the new etiology.

Biography

Biography: Hans von Holst,

Abstract

Cytotoxic brain tissue edema, which is found in both grey and white matter cells, is a complicated secondary consequence to ischemic injury following cerebral diseases such as stroke and traumatic brain injury (TBI). To some extent the pathophysiological mechanisms are known, however far from complete. A new hypothesis regarding the etiology to cytotoxic brain edema is presented. The hypothesis is that the internal energy of semi-static mechanical forces following stroke and external energy of dynamic impact due to TBI result in the disruption of non-covalent and covalent bonds in protein and nucleotide structures. The unfolded proteins attract water molecules while the disruption of nucleotides such as adenosine-tri-phosphates causes a dysfunction in ion hemostasis and which may tentatively explain the etiology to cytotoxic edema. Our studies using computer models show that the kinetic energy following an impact to the head has the potential to break the chemical bonds in the protein and nucleotide structures resulting in cytotoxic brain tissue edema. Since folding of mature proteins is very much dependent on normal energy supply, the protein synthesis cannot continue during the ischemic process. Under such conditions very little of the energy rich ATP can be produced and which may result in disturbance between extra- and intracellular ion metabolism. By using a folded protein in laboratory investigation the present hypothesis has the potential to be confirmed and, hence, develop new drugs for therapeutic use.